Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
- Combining Angiogenesis-Targeted Treatments for Liver Cancer
(Posted: 05/29/2012) - In this trial, patients with unresectable hepatocellular carcinoma who are ineligible for a liver transplant or other local therapies will be given oral sorafenib at the standard approved dose and intravenous TRC105.
- Testing Vascular Disruption Combined with Chemotherapy for Advanced Solid Tumors
(Posted: 04/17/2012) - In this phase I/II trial, doctors will assess the safety and tolerability of intravenous crolibulin and cisplatin in patients with advanced solid tumors, establish the maximum tolerated dose for the combination, and randomly assign patients with anaplastic thyroid cancer to receive crolibulin and cisplatin or cisplatin alone.
- Combining Systemic Therapies for Patients with Advanced Liver Cancer
(Posted: 03/20/2012) - In this phase III trial, patients with unresectable, locally advanced or metastatic primary liver cancer who have good liver function (Child-Pugh score A) will receive sorafenib and be randomly assigned to also receive either doxorubicin or no additional therapy.
- Exploring the Anticancer Potential of Valproic Acid in Advanced Thyroid Cancer
(Posted: 03/07/2012) - In this trial, patients with advanced thyroid cancers of follicular cell origin whose tumors are not sensitive to radioactive iodine therapy will take valproic acid for 10 weeks and then undergo a radioactive iodine uptake test.
- Surgical Removal of Primary Tumor for Metastatic Breast Cancer
(Posted: 02/21/2012) - In this clinical trial, women with newly diagnosed metastatic breast cancer who are undergoing systemic therapy and whose disease does not progress within 16 weeks of starting that therapy will be randomly assigned to continue systemic therapy or to undergo surgical resection of their primary tumor.